法国视神经脊髓炎谱系疾病诊断与管理指南
该法国指南针对视神经脊髓炎谱系疾病(NMOSD)指出,视神经炎是最常见表现,可致快速严重视力丧失且常为双侧;脊髓炎呈长节段中央型病灶,可致四肢瘫、感觉障碍、神经痛和括约肌功能障碍;极后区综合征表现为顽固恶心、呕吐和严重呃逆。诊断依靠血清抗AQP4抗体检测。发作应按急症处理,立即给予静脉糖皮质激素和血浆置换,无需等待抗体确认。维持治疗包括靶向B淋巴细胞、IL-6受体、补体C5的单克隆抗体及非选择性免疫抑制治疗,按耐受性选择。
要点
- 发作应按急症处理,立即静脉糖皮质激素联合血浆置换,不必等待AQP4抗体确认。
- 视神经炎最常见,可快速严重视力丧失、常双侧,MRI示视神经长节段病灶多累及后段,可延及视交叉。
- 脊髓炎呈长节段中央型病灶,可致四肢瘫、感觉障碍、神经痛及括约肌功能障碍。
- 极后区综合征表现为恶心、呕吐和严重呃逆,常对常规治疗抵抗,可能需要住院。
- 维持治疗可选靶向B淋巴细胞、IL-6受体、补体C5的单克隆抗体或非选择性免疫抑制治疗,按耐受性选择。
适用人群与场景
- 视神经脊髓炎谱系疾病(NMOSD)患者,表现为视神经炎、脊髓炎或极后区综合征等。
- 妊娠期被视为高风险,需定期神经科和产科监测,产后发作风险增加。
诊断标准与关键阈值
- 诊断通过检测血清抗AQP4抗体确认。
处置流程与药物剂量
- 发作应按急症处理,立即给予静脉糖皮质激素和血浆置换,无需等待抗体确认。
- 维持治疗包括靶向B淋巴细胞、白细胞介素-6受体、补体C5的单克隆抗体及非选择性免疫抑制治疗,根据耐受性选择。
- 硫唑嘌呤或吗替麦考酚酯等传统治疗较少用作一线,但可根据临床情况使用。
- 随访为多学科,包括神经科,并根据症状进行眼科、神经心理、尿动力学或后遗症残疾咨询。
- 治疗性患者教育和患者组织支持对改善生活质量和治疗依从性至关重要。
- 妊娠期需定期神经科和产科监测。
红旗征与不能漏的情况
- 视神经炎可致快速且常严重的视力丧失,有时为双侧,长期有极低视力风险。
- 脊髓炎可致四肢瘫、感觉障碍、神经痛和括约肌功能障碍。
- 极后区综合征的恶心、呕吐和严重呃逆常对常规治疗抵抗,可能需要住院。
研究设计与关键结果
- 该指南由法国制定,涵盖NMOSD的诊断与管理,强调发作按急症处理及快速个体化管理以限制功能后遗症和残疾。
证据类型、等级与局限
- 证据类型:指南(法国指南)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者强调发作的快速个体化管理及预防复发对限制功能后遗症和残疾至关重要。
- 作者指出治疗性患者教育和患者组织支持对改善生活质量和治疗依从性至关重要。
指南或共识出处
- 法国视神经脊髓炎谱系疾病诊断与管理指南(Rev Neurol (Paris))。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system, characterized by severe attacks. Optic neuritis is the most common clinical manifestation, leading to a rapid and often severe loss of vision, which is sometimes bilateral, with frequent sequelae and a risk of very low visual acuity in the long-term. Magnetic resonance imaging (MRI) reveals extensive lesions of the optic nerve, mostly involving the posterior part of the nerve and sometimes extending to the optic chiasm. Myelitis manifests as longitudinally extensive and centrally located spinal cord lesions, which may lead to tetraplegia, sensory disturbances, neuropathic pain and sphincter dysfunction. Area postrema syndrome presents with nausea, vomiting, and severe hiccups, which are often resistant to conventional treatments and may require hospitalization. Diagnosis is confirmed by the detection of anti-aquaporine 4 (AQP4) antibodies in the serum. Attacks should be treated as an emergency, with intravenous (IV) corticosteroids and plasma exchange, without waiting for antibody confirmation. Maintenance therapy includes monoclonal antibodies targeting B lymphocytes, interleukin-6 receptor, complement C5 and non-selective immunosuppressive treatments, according to profile of tolerance. Conventional treatments such as azathioprine or mycophenolate are less commonly used as first-line therapies but remain possible depending on the clinical context. Follow-up is multidisciplinary, with neurological, and according to the symptoms ophthalmological, neuropsychological, urodynamic or sequellar disability consultations. Therapeutic patient education and support from patient organizations are essential for improving quality of life and treatment adherence. Pregnancy is considered high-risk, requiring regular neurological and obstetric monitoring, as the risk of attack increases in the postpartum period. Finally, the rapid and individualized management of attacks as well as the prevention of relapses is crucial to limit functional sequelae and disability.
参考来源
- Giorgi L, Marignier R, Pique J, et al. French guidelines for the diagnosis and management of neuromyelitis optica spectrum disorder. Rev Neurol (Paris). 2026. PMID: 42481362. doi:10.1016/j.neurol.2026.06.004
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。